Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;50(2):92-105.
doi: 10.1016/j.tibs.2024.11.006. Epub 2024 Dec 26.

Protein shapeshifting in necroptotic cell death signaling

Affiliations
Review

Protein shapeshifting in necroptotic cell death signaling

Hanadi Hoblos et al. Trends Biochem Sci. 2025 Feb.

Abstract

Necroptosis is a mode of programmed cell death executed by the mixed lineage kinase domain-like (MLKL) pseudokinase following its activation by the upstream receptor-interacting protein kinase-3 (RIPK3), subsequent to activation of death, Toll-like, and pathogen receptors. The pathway originates in innate immunity, although interest has surged in therapeutically targeting necroptosis owing to its dysregulation in inflammatory diseases. Here, we explore how protein conformation and higher order assembly of the pathway effectors - Z-DNA-binding protein-1 (ZBP1), RIPK1, RIPK3, and MLKL - can be modulated by post-translational modifications, such as phosphorylation, ubiquitylation, and lipidation, and intermolecular interactions to tune activities and modulate necroptotic signaling flux. As molecular level knowledge of cell death signaling grows, we anticipate targeting the conformations of key necrosomal effector proteins will emerge as new avenues for drug development.

Keywords: allostery; kinase; phosphorylation; programmed cell death; protein conformation; pseudokinase.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ALS and JMM contribute to a project developing necroptosis pathway inhibitors in collaboration with Anaxis Pharma Pty Ltd. JMM has received research funding from Anaxis Pharma Pty Ltd. JMM is a member of the TIBS editorial advisory board.

Similar articles

Cited by

MeSH terms

LinkOut - more resources